|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/14 | |
| A61K 9/51 | |||
| A61K 31/551 |
| (11) | Patento numeris | 1827374 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 05851701.2 |
| Europos patento paraiškos padavimo data | 2005-11-16 | |
| (97) | Europos patento paraiškos paskelbimo data | 2007-09-05 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2014-11-05 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2005/041470 |
| Data | 2005-11-16 |
| (87) | Numeris | WO 2006/055603 |
| Data | 2006-05-26 |
| (30) | Numeris | Data | Šalis |
| 628748 P | 2004-11-16 | US |
| (72) |
LIVERSIDGE, Gary, US
JENKINS, Scott, US
LIVERSIDGE, Elaine, US
|
| (73) |
Alkermes Pharma Ireland Limited,
Connaught House 1 Burlington Road, Dublin 4,
IE
|
| (54) | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS |
| INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS |